TABLE 4.
In vitro activities of ceftazidime-avibactam and comparator agents tested against 1,627 ceftazidime-nonsusceptible P. aeruginosa isolates collected in 2012 to 2014 from patients in four geographic regions
| Region (no. of isolates) | Antimicrobial agenta | MIC90 (μg/ml) | % Susceptibleb |
|---|---|---|---|
| All (1,627) | Ceftazidime-avibactam | 64 | 65.4 |
| Ceftazidime | >128 | 0 | |
| Cefepime | >16 | 19.7 | |
| Piperacillin-tazobactam | >128 | 5.4 | |
| Doripenem | >4 | 32.4 | |
| Meropenem | >8 | 31.8 | |
| Imipenem | >8 | 26.1 | |
| Colistin | 1 | 99.1 | |
| Amikacin | >32 | 65.7 | |
| Levofloxacin | >4 | 32.3 | |
| Europe (880) | Ceftazidime-avibactam | 64 | 67.3 |
| Ceftazidime | 128 | 0 | |
| Cefepime | >16 | 21.6 | |
| Piperacillin-tazobactam | >128 | 5.6 | |
| Doripenem | >4 | 30.5 | |
| Meropenem | >8 | 29.6 | |
| Imipenem | >8 | 23.2 | |
| Colistin | 1 | 99.5 | |
| Amikacin | >32 | 66.0 | |
| Levofloxacin | >4 | 30.8 | |
| Asia/South Pacific (305) | Ceftazidime-avibactam | 128 | 68.9 |
| Ceftazidime | >128 | 0 | |
| Cefepime | >16 | 21.0 | |
| Piperacillin-tazobactam | >128 | 7.2 | |
| Doripenem | >4 | 42.0 | |
| Meropenem | >8 | 43.9 | |
| Imipenem | >8 | 38.4 | |
| Colistin | 1 | 98.7 | |
| Amikacin | >32 | 80.0 | |
| Levofloxacin | >4 | 43.0 | |
| Latin America (310) | Ceftazidime-avibactam | 64 | 60.3 |
| Ceftazidime | >128 | 0 | |
| Cefepime | >16 | 16.1 | |
| Piperacillin-tazobactam | >128 | 4.2 | |
| Doripenem | >4 | 26.8 | |
| Meropenem | >8 | 26.5 | |
| Imipenem | >8 | 22.6 | |
| Colistin | 1 | 98.7 | |
| Amikacin | >32 | 53.2 | |
| Levofloxacin | >4 | 26.8 | |
| Middle East/Africa (132) | Ceftazidime-avibactam | 64 | 56.8 |
| Ceftazidime | 128 | 0 | |
| Cefepime | >16 | 12.1 | |
| Piperacillin-tazobactam | >128 | 3.0 | |
| Doripenem | >4 | 35.6 | |
| Meropenem | >8 | 31.8 | |
| Imipenem | >8 | 25.0 | |
| Colistin | 1 | 98.5 | |
| Amikacin | >32 | 59.9 | |
| Levofloxacin | >4 | 31.1 |
a
Colistin was tested in the presence of a final concentration of 0.002% polysorbate 80.
b
Values are based on CLSI breakpoints, except for ceftazidime-avibactam, for which FDA breakpoints were used.